Tandem Health

Tandem Health

AI-powered clinical documentation for Swedish providers

Overview

Tandem Health streamlines clinical documentation by using AI to help healthcare providers write medical notes during patient visits. Clinicians can verbalize findings, and the AI automatically turns speech into structured notes without interrupting the consultation, freeing time for patient care. The service runs on a subscription basis for healthcare providers in Sweden, with all data encrypted and processed within Sweden to comply with EU rules. Aimed at reducing administrative workload, the solution supports more efficient workflows and better patient involvement in care. Compared to competitors, Tandem Health emphasizes data locality (Sweden-only processing), strong data privacy, and a seamless, non-disruptive note-taking experience, backed by leadership with healthcare and AI backgrounds. The goal is to cut documentation time, improve clinician efficiency, and advance healthcare practices through reliable, privacy-conscious AI tooling.

About Tandem Health

Simplify's Rating
Why Tandem Health is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Enterprise Software

AI & Machine Learning

Healthcare

Company Size

51-200

Company Stage

Series A

Total Funding

$59.5M

Headquarters

Stockholms kommun, Sweden

Founded

2023

Get referred to Tandem Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • June 2026 Philips SpeechMike Ambient partnership broadens distribution through a trusted hardware channel.
  • Doctor Care Anywhere’s embedded rollout covers 60,000 monthly consultations, proving scaled UK demand.
  • July 2026 Series A funding from Kinnevik and Northzone funds hiring, product depth, and expansion.

What critics are saying

  • Heidi Evidence blocking UK NHS emails in May 2026 shows regulatory access can vanish overnight.
  • Integration complexity across 100+ EHRs raises failure risk, delaying deployments and customer renewals.
  • Nuance, Microsoft, and Heidi pressure Tandem’s margins as ambient documentation commoditizes.

What makes Tandem Health unique

  • Tandem Health’s EU MDR Class IIa status differentiates it from weaker-regulated scribes.
  • Juvoly acquisition, January 2026, adds Dutch primary-care depth and local market reach.
  • More than 100 medical record integrations across Europe make Tandem unusually enterprise-ready.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$59.5M

Above

Industry Average

Funded Over

2 Rounds

Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Above Average

Industry standards

$15M
$8.2M
Discord
$15M
Canva
$30M
Kalshi
$50M
Tandem Health

Benefits

Flexible Work Hours

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

4%

2 year growth

23%
Breakit
Jul 14th, 2026
Swedish healthtech Tandem Health on track after $56.5M round from Kinnevik and Northzone

Swedish healthtech startup Tandem Health has raised over half a billion Swedish kronor in venture capital from investors including Kinnevik and Northzone. The company develops AI-based journal tools for healthcare providers. Chief executive and co-founder Lukas Saari told Breakit the company is "building for the long term" and following its plan. Previously, details about the startup's sales performance had not been publicly disclosed. The funding round, which closed last year, represents significant backing from prominent Scandinavian investors. Tandem Health's technology aims to streamline documentation processes in healthcare settings through artificial intelligence.

Streets Heaver
Jul 2nd, 2026
Streets Heaver partners with Tandem Health to bring enterprise-grade Ambient AI documentation into compucare(r) Clinician Pro.

Streets Heaver partners with Tandem Health to bring enterprise-grade Ambient AI documentation into compucare(r) Clinician Pro. By Holly Johnson, Marketing Executive Streets Heaver Healthcare Computing is pleased to announce a strategic partnership with Tandem Health, bringing enterprise-grade Ambient AI documentation directly into Compucare Clinician Pro. The integration will provide healthcare organisations with a fully embedded experience, enabling clinicians to capture consultations, generate structured clinical documentation and correspondence, and return approved outputs directly into the patient record, all without leaving Compucare. This partnership marks another significant milestone in Streets Heaver's AI strategy, complementing the company's native AI platform, NIVA, while reinforcing its commitment to delivering safe, governed and practical AI solutions for private healthcare providers and NHS Private Patient Units. As one of the UK's most widely adopted private healthcare management platforms, Compucare continues to evolve around the needs of clinicians, operational teams and healthcare leaders. This latest development reflects a clear focus on reducing administrative burden, improving workflow efficiency and supporting better patient care through intelligent technology. A native experience built for clinical workflows. Unlike standalone AI tools that operate separately from core clinical systems, the Tandem integration has been designed as a seamless part of the Compucare experience. Clinicians will be able to launch Tandem directly from within Compucare Clinician Pro. Patient and appointment context will flow through automatically, consultations will be captured and structured in real time, and approved documentation will return directly into the patient's record. The result is a more streamlined clinical workflow that reduces documentation burden while maintaining clinician oversight and control. Announcing the partnership, Benedict Heaver, CEO of Streets Heaver Healthcare Computing, said: "For its customers, this offers a native, embedded experience where clinicians launch Tandem directly from inside Compucare, consultations are captured and structured automatically, and approved output flows straight back into your patient record. Streets Heaver has spent months evaluating the Ambient AI landscape carefully. What set Tandem apart was not just the product, it was the alignment. They are MDR Class IIa certified for their Scribe & Coding Assistant, externally audited, and built for the enterprise private healthcare environment Streets Heaver serve. This will sit alongside its native AI, NIVA, which is already baked into its products and extends its AI vision, in a safe and transparent way. To its existing customers, Streets Heaver'll be in touch over the coming weeks to talk through what this means for you. To the wider market, this is building on its existing investments in AI across its platform in a way that's safe, governed and useful." Why Tandem Health? Founded in Stockholm, Tandem Health has emerged as one of Europe's leading Ambient AI healthcare companies, helping clinicians reduce documentation time through AI-powered clinical note generation and workflow support. The company's focus on clinical governance, compliance and healthcare-specific design closely aligns with Streets Heaver's approach to healthcare technology. Dr Katie Baker, GTM Director, UK & Ireland at Tandem Health, commented on the partnership: "What excites me about this partnership is that Compucare approached it the way we do - carefully, with governance front of mind. For healthcare organisations, that means AI documentation that's not just capable, but certified and enterprise-ready from day one." Over recent months, Streets Heaver undertook a detailed review of the Ambient AI market, assessing a range of solutions against the requirements of private healthcare organisations and NHS Private Patient Units. While functionality was an important consideration, governance, regulatory standards and long-term strategic fit were equally critical. Tandem stood out for three key reasons: * MDR Class IIa certification for its Scribe & Coding Assistant * An externally audited development and quality process * A commitment to deep platform integration rather than operating as a disconnected third-party application Andy Robinson, Head of Technology at Streets Heaver, explained: "The integration Streets Heaver is delivering isn't a bolt-on. Clinicians will launch Tandem directly from Compucare, patient and appointment context will flow through automatically, and approved notes and correspondence will return directly to the patient record. What made Tandem the right partner was the combination of MDR Class IIa certification, an externally audited build process and a genuine commitment to deep integration. They build the way Streets Heaver build: modular, deliberate and enterprise-first. Complementing this is its native AI, NIVA, already integrated into its products, helping to extend its AI vision while maintaining a strong focus on safety and transparency." Why Ambient AI matters now. The partnership reflects a broader shift in what clinicians expect from healthcare technology. Today's clinicians are accustomed to intuitive, consumer-grade experiences in their everyday lives. Increasingly, they expect the same simplicity and responsiveness from the systems they use at work. At the same time, healthcare organisations face growing documentation requirements, increasing administrative pressure and rising volumes of clinical data. The challenge is not simply digitising paper processes. The challenge is helping clinicians access the right information, at the right time, without introducing additional complexity into their workflows. Streets Heaver's Customer Success Manager, Mark Wilkinson, believes the integration addresses one of the biggest frustrations clinicians face during consultations: balancing documentation with patient interaction. "Tandem will be a big step forward for clinicians. Many are already using AI-powered dictation tools like Tandem to capture their assessment notes, but integrating that capability directly into Clinician Pro is the missing piece. Clinicians use dictation because they want to focus their full attention on the patient during consultations. Having to stop and write notes throughout the conversation is distracting, whereas this integration allows documentation to happen seamlessly without interrupting patient care." At Streets Heaver, this philosophy has shaped the development of Compucare Clinician Pro, where usability, workflow alignment and information relevance are central design priorities. As Candy Mussett, Head of Operations at Streets Heaver, explains: "Healthcare technology should feel like a natural extension of clinical practice. Clinicians need systems that are intuitive, reliable and designed around the way they actually work." Stuart Hymers, Head of Commercials, adds: "Technology works best when it's designed with clinicians, not for clinicians. The closer we align software to real-world clinical workflows, the more value it delivers." Ambient AI represents an important step in that journey. By reducing the time spent on documentation and administration, clinicians can focus more of their attention on patient interactions and clinical decision-making. Building on the Vision for AI at Streets Heaver. This partnership complements Streets Heaver's wider AI roadmap and ongoing investment in innovation across the Compucare platform. Alongside Tandem's Ambient AI capabilities, Streets Heaver continues to develop NIVA, its native AI platform designed to deliver intelligent assistance across healthcare workflows. The company's vision is clear: AI should support clinicians and operational teams by reducing complexity, surfacing relevant information and improving efficiency, while maintaining transparency, governance and human oversight. As healthcare organisations continue to generate increasing volumes of clinical and operational data, the opportunity for AI extends beyond documentation alone. Future innovation will focus on helping users access meaningful insights faster, identify trends more effectively and make better-informed decisions without increasing workload. The objective is not to replace clinical judgement. It is to support it. Looking ahead. Hosted Compucare customers will be among the first to benefit from the deep integration capabilities being introduced through the partnership. Over the coming weeks, Streets Heaver and Tandem Health will begin engaging with customers to demonstrate the technology, discuss implementation options and explore how Ambient AI can support different clinical environments. This partnership represents another step towards a future where healthcare technology becomes increasingly intuitive, intelligent and aligned to the realities of clinical practice. Book a demonstration. Book a personalised demonstration to discover how Compucare, Tandem Health and NIVA are helping healthcare organisations reduce administrative burden, improve clinician productivity and deliver more efficient patient care.

Breakit
Jun 29th, 2026
Humlegården welcomes Tandem Health to Kungsgatan.

Humlegården welcomes Tandem Health to Kungsgatan. The rapidly growing AI company Tandem Health is moving to Humlegården's property at Kungsgatan 12-14 in Stockholm. The premises cover approximately 2,250 square meters and the move-in takes place in August 2026. Published: June 29, 2026 07:00 Updated: June 29, 2026 07:00 Kungsgatan 12-11, photo by Emil Fagander Tandem Health was founded in 2023 and offers an AI solution used in healthcare. Today, the company has 150 employees and offices in ten cities across Europe. When their office needs changed, the choice fell on Humlegården's property at Kungsgatan 12-14, in one of Stockholm's best locations just next to Stureplan. Tandem Health was looking for premises that could support the company's continued expansion. The new office spans 2,250 square meters across two floors. - Breakit look forward to creating its very own home on Kungsgatan as the next step in its growth journey. Central and in the heart of Stockholm's growing tech scene. The new premises give Breakit the conditions to welcome even more talent, create an environment that inspires and where one wants to spend a lot of time, says Nelly Tranaas, Head of Operations, Tandem Health. The office is a hub for operations Tandem Health is a company with high office presence that views the premises as a central hub for its operations. Workspaces are combined with large social areas and space for internal gatherings. The own premises are combined with access to the building's shared functions, such as a green courtyard, changing rooms, bicycle parking, and garage. - Breakit is very happy that Tandem Health chooses to establish itself with Breakit on Kungsgatan. This creates a modern and attractive workplace in one of Stockholm's most central locations. The setting is very well suited for an innovative and expanding company with high ambitions, where the office truly plays a central role in the operations, says Jens Folkesson, Head of Property and Leasing at Humlegården Fastigheter. Jens Folkesson Head of Property and Leasing, Humlegården Fastigheter Tel: 070-678 01 53 E-mail: [email protected] Madeleine Castenvik Holt Head of Marketing and Communications, Humlegården Fastigheter Tel: 072-058 21 75 E-mail: [email protected] Humlegården Fastigheter AB (publ) is an active real estate company with long-term owners and a well-positioned property and project portfolio. Breakit is part of the Länsförsäkringar group, Sweden's only customer-owned and locally anchored banking and insurance group. Humlegården owns, manages, and develops mainly office properties in the Stockholm region. Breakit has 97 employees and own 61 properties valued at SEK 42.5 billion (December 31, 2025). At Humlegården, Breakit strive to develop sustainable and attractive work and urban environments. Breakit create this through active property management and development projects consisting of new construction and development of existing properties. Read more at www.humlegarden.se

Sifted
Jun 23rd, 2026
Tandem Health scales to 5,000 healthcare providers across 12 countries after $50M Series A

Swedish medical copilot startup Tandem Health has expanded rapidly since raising $50 million in Series A funding last June. The company has grown its user base from just over 1,000 healthcare providers to 5,000 and now operates across 12 countries in Europe. Tandem Health develops AI-powered tools designed to assist healthcare professionals with clinical tasks. The startup's expansion reflects growing adoption of AI copilots in European healthcare settings.

IATROX AI LTD
Jun 15th, 2026
Tandem CDS vs Heidi Evidence: how two scribe companies' decision-support tools compare on evidence and regulation.

Tandem CDS vs Heidi Evidence: how two scribe companies' decision-support tools compare on evidence and regulation. Two of the best-known names in clinical documentation, Tandem and Heidi, have both moved beyond the scribe and into clinical decision support. Tandem launched clinical decision support inside Ask Tandem; Heidi launched Heidi Evidence, an evidence layer it built after acquiring the UK company AutoMedica. On paper they answer the same question - help clinicians find and apply trusted medical knowledge - but they take different routes on regulation, sourcing and, most consequentially for UK clinicians, availability. Regulatory posture. Tandem has been explicit about climbing the regulatory ladder. Its AI scribe, coding assistant and clinical decision support are all CE marked under EU MDR as Class IIa medical devices, externally assessed by a notified body. For a decision-support product, that is a meaningful, independently checked baseline. Heidi's position is more layered. Its AI scribe is registered with the MHRA as a Class I device for summarisation functionality. Heidi Evidence, however, is newer, and independent coverage has noted that its UK regulatory status is still to be confirmed. So while both companies hold device registrations for their scribes, Tandem currently carries the firmer regulatory footing specifically for its decision-support product. Sourcing and evidence integrity. Both lean hard on cited answers, and both make a point of source transparency. Heidi Evidence is built in partnership with named clinical sources - HealthPathways, EMGuidance, MIMS, Vidal, NICE and BMJ Group - and is positioned as ad-free, providing concise summaries with transparent citations and verbatim excerpts. Heidi has framed this explicitly against ad-supported consumer AI, arguing that the integrity of clinical evidence should be non-commercial. It also lets clinicians upload their own sources, and is built in part on Anthropic's Claude models. Tandem's CDS draws on national guidelines plus locally uploaded protocols, and is designed to use the context of the documented visit. Its evidence story is anchored less in named content partnerships and more in the regulatory assurance of its Class IIa assessment. Both are new enough that real-world clinical validation is still emerging; neither should be treated as having a long published track record in decision support yet. The decisive factor for UK clinicians: availability. This is where the comparison stops being academic. Heidi Evidence reportedly began blocking UK NHS email addresses at enrolment in May 2026 - part of a wider pattern in which several clinical AI tools have stepped back from UK NHS access amid regulatory uncertainty. Tandem's CDS, by contrast, is available to selected customers across Europe and the UK. The result is a paradox worth naming: Heidi Evidence is built on UK-relevant sources like NICE and BMJ Group, yet reportedly excludes UK NHS clinicians at sign-up, while Tandem - a Swedish company - has pursued the higher regulatory class and stayed in the UK market. | Dimension | Tandem CDS | Heidi Evidence | | Product type | In-consultation decision support | Evidence layer (standalone or with scribe) | | Regulatory class | CE marked EU MDR Class IIa (notified-body assessed) | Scribe is MHRA Class I; Evidence regulatory status reportedly TBC | | Sourcing | National guidelines + local uploaded protocols | NICE, BMJ, MIMS, Vidal, HealthPathways, EMGuidance; user uploads | | Commercial model | Enterprise / EHR-integrated | Free for individual clinicians; ad-free | | UK NHS availability | Available (selected UK customers) | Reportedly blocking UK NHS emails at enrolment (May 2026) | | Clinical validation | Emerging | Emerging | Where iatroX sits. For a UK clinician, the practical question is not only "which decision-support tool is best?" but "which one can I actually use, grounded in UK practice?" iatroX is built around that gap: it is a UK-registered, MHRA-listed Class I clinical AI, free to use, grounded in NICE, CKS, SIGN and the SmPC. iatroX is deliberately a different layer from Tandem's in-consultation CDS - it informs the clinician's own judgement rather than automating or directing the decision, which is why it sits at Class I rather than Tandem's Class IIa. But unlike Heidi Evidence, it remains available to UK NHS clinicians, and unlike US-centric tools, it is built for UK guidelines from the ground up. The point is not that iatroX out-regulates anyone - Tandem's Class IIa is a higher bar - but that the UK knowledge layer is one a clinician can open today. And Class I being self-declared does not mean ungoverned: iatroX's registration is backed by a full clinical risk-management file and safety case, independently reviewed. Frequently asked questions. Is Heidi Evidence available to UK NHS clinicians? According to independent reporting, Heidi Evidence began blocking UK NHS email addresses at enrolment in May 2026. UK clinicians should check current availability directly, as the position may change. How does Tandem's CDS differ from Heidi Evidence on regulation? Tandem's clinical decision support is CE marked under EU MDR as a Class IIa device, externally assessed by a notified body. Heidi's scribe is MHRA Class I, but the regulatory status of Heidi Evidence specifically has been reported as still to be confirmed. Are these tools clinically validated? Both are recent, and real-world clinical validation for their decision-support products is still emerging. Neither has a long published evidence base in decision support yet, so claims should be read with that in mind. What is the UK-available alternative? iatroX is a free, UK-registered (UKCA-marked Class I) clinical AI grounded in NICE, CKS, SIGN and the SmPC, and remains available to UK NHS clinicians as a knowledge and reference layer.

Recently Posted Jobs

Sign up to get curated job recommendations

Tandem Health is Hiring for 10 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →